Full-Time
Posted on 7/17/2025
Physician groups optimized for value-based payments
$115k - $130k/yr
Washington, USA + 1 more
More locations: California, USA
Remote
Candidate must be located in either Washington or California.
| , |
Privia Health is a national physician organization that aligns reimbursements with quality and outcomes to transform the healthcare delivery experience for providers and consumers. It partners with health plans, health systems, and employers to cut unnecessary costs, improve outcomes, and boost patient health. The company runs a platform built on physician leadership development, scalable systems, and proprietary technology to organize and scale physician groups into high-performance networks, reducing administrative burdens and giving doctors autonomy while supporting growth. Its approach centers on capital-efficient physician alignment models that enable expansion and closer coordination among providers, payers, and employers. By focusing on outcomes and efficiency rather than volume, Privia Health aims to lower costs, improve care quality, and empower clinicians.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Alexandria, Virginia
Founded
2007
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
Paid Vacation
Wellness Program
Performance Bonus
Privia Health earns 2026 HFMA MAP Award for Revenue Cycle Excellence. Rhea-AI Impact Rhea-AI Sentiment (Very Positive) Rhea-AI summary. Privia Health (Nasdaq: PRVA) earned the 2026 HFMA MAP Award for High Performance in Revenue Cycle, marking recognition in nine of the last ten years. The award reflects sustained excellence across MAP Keys(R) metrics such as net collection rate, AR performance, denial prevention, and cost to collect. Privia's multi-year transformation - analytics, AI automation, provider engagement, and scalable operating models - drove strong MAP benchmark results and the national award presented March 18 at the HFMA Revenue Cycle Conference. 03/24/2026 - 09:00 AM ARLINGTON, Va., March 24, 2026 (GLOBE NEWSWIRE) - Privia Health Group, Inc. (Nasdaq: PRVA) announced that its network of affiliated medical groups, collectively Privia Medical Group, has been named a recipient of the 2026 MAP (Measure, Apply, Perform) Award for High Performance in Revenue Cycle, sponsored by the Healthcare Financial Management Association (HFMA). Privia Health has been recognized by HFMA for its revenue cycle capabilities and performance in nine of the last ten years. The MAP Award is one of the healthcare industry's most respected distinctions, highlighting organizations that demonstrate sustained excellence across key revenue cycle metrics, including net collection rate, accounts receivable performance, denial prevention, and cost to collect. As a national award winner, Privia Health met or exceeded industry-standard revenue cycle benchmarks (MAP Keys(R) while advancing patient-centered best practices aligned with HFMA's Healthcare Dollars & Sense(R) initiative. "Consistent recognition from HFMA reflects the strength of our revenue cycle operations and the collaboration across our teams to deliver a seamless, patient-centered financial experience," said Melanie Suranto, Senior Vice President, Revenue Cycle Management and Credentialing at Privia Health. "This achievement is a testament to the discipline, innovation, and commitment of our teams nationwide to deliver value for both clinicians and patients." The award was presented on March 18 at the HFMA Revenue Cycle Conference in Arlington, Texas. Privia Health's performance was driven by a multi-year transformation strategy focused on: * Advanced analytics and KPI discipline to drive accountability and transparency * AI-enabled automation and workflow optimization to improve efficiency and accuracy * Enhanced provider engagement and education to strengthen front-end performance * Scalable operating models to support growth across diverse markets These efforts resulted in strong performance across HFMA's MAP benchmarks, reinforcing Privia Health's position as a leader in revenue cycle innovation and execution. About Privia Health Privia Health(TM) is one of the largest physician enablement companies in the United States with a presence in 24 states and the District of Columbia. Privia builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. Privia collaborates with medical groups, health plans and health systems to optimize 1,300+ physician practices, improve the patient experience for 5.8+ million patients, and reward 5,300+ physicians and advanced practitioners for delivering high-value care. Privia's mission is to transform healthcare delivery to achieve better outcomes, lower costs, and improve the health of communities and the well-being of providers. For more information, visit priviahealth.com. Contact Robert Borchert SVP, Investor & Corporate Communications [email protected] 817.783.4841 Faq. What did Privia Health announce about the 2026 HFMA MAP Award (PRVA)? Privia Health announced it received the 2026 HFMA MAP Award for Revenue Cycle Excellence, a national recognition. According to the company, this marks MAP recognition in nine of the last ten years and reflects strong performance across HFMA MAP Keys(R) metrics. Which revenue cycle metrics led to Privia Health winning the 2026 MAP Award (PRVA)? The award highlighted performance in net collection rate, accounts receivable, denial prevention, and cost to collect. According to the company, meeting or exceeding HFMA MAP Keys(R) benchmarks across these metrics drove the recognition. When and where was Privia Health presented the 2026 HFMA MAP Award (PRVA)? The award was presented on March 18, 2026, at the HFMA Revenue Cycle Conference. According to the company, the presentation took place during the conference in Arlington, Texas, recognizing national high performance. What operational changes did Privia Health cite as driving MAP Award success (PRVA)? Privia Health cited advanced analytics, AI-enabled automation, enhanced provider engagement, and scalable operating models as drivers of success. According to the company, these multi-year initiatives improved efficiency, accuracy, and front-end performance. How often has Privia Health been recognized by HFMA with MAP awards (PRVA)? Privia Health has been recognized by HFMA in nine of the last ten years for revenue cycle performance. According to the company, this reflects sustained, repeat recognition across a multi-year period. What does the 2026 MAP Award mean for Privia Health patients and clinicians (PRVA)? The award signals Privia Health's emphasis on a seamless, patient-centered financial experience and clinician value. According to the company, disciplined revenue cycle practices aim to improve transparency, reduce denials, and support clinicians nationwide.
Wall Street analysts project substantial upside for YETI, Saia and Privia Health, but independent analysis suggests caution. YETI, a maker of outdoor gear, trades at $36.42 per share with a consensus price target of $50.60. However, its 11.3% annual revenue growth over five years lags peers, whilst declining returns on capital signal ineffective management decisions. Freight transportation provider Saia trades at $321.12, valued at 30.5x forward P/E. The company faces challenges with disappointing shipment volumes and a negative 0.4% free cash flow margin. Healthcare technology firm Privia Health shows a $31.85 price target but operates at subscale with $2.12 billion in revenue and negative returns on capital. Analysts rarely issue sell ratings, partly because their firms seek business from covered companies.
Privia Health Group has reported significant progress in colorectal cancer screening outcomes through its EHR-integrated patient outreach programme, which has been deployed at national scale. The results show screening rates exceeding key benchmarks and demonstrate measurable gains in preventive care achieved through technology-focused partnerships. The company, which reported 2025 revenue of $2.12 billion and net income of $22.92 million, embeds outreach, test ordering, results and follow-up directly into electronic health records. This approach supports quality metrics underlying many value-based contracts. Trading at $23.27 per share, Privia Health has gained 5.8% over the past 30 days but declined 8.9% over one year. The screening programme highlights how the company's physician-enablement model converts its technology into measurable care outcomes, potentially strengthening its position in value-based care markets.
Privia Health, a physician enablement company, reported full-year 2025 results exceeding guidance, with adjusted EBITDA of $125.5 million, up 38.8% year-over-year. The company achieved net income of $30.7 million and generated $163.4 million in operating cash flow, ending the year with $479.7 million in cash and no debt. The Arlington-based company, which operates across 24 states, supports over 5,300 physicians serving 5.8 million patients. All operating and financial metrics met or exceeded the high end of guidance ranges. For 2026, Privia projects adjusted EBITDA growth of approximately 20% at the midpoint, expecting to convert roughly 80% of adjusted EBITDA to free cash flow. The company anticipates ending 2026 with around $600 million in cash whilst pursuing organic provider growth and maintaining performance in value-based care arrangements.
Privia Health will report Q4 earnings tomorrow before market open. The healthcare technology company beat revenue expectations last quarter with $580.4 million, up 32.5% year-on-year, whilst also exceeding EPS estimates. Analysts expect revenue to grow 12% year-on-year this quarter, improving from the 4.6% increase recorded in Q4 last year. Analysts have largely reconfirmed their estimates over the past 30 days, and Privia Health has historically exceeded Wall Street's expectations. The stock is down 5.4% over the past month, compared to a 1.1% average decline across the healthcare technology segment. Shares currently trade at $21.70, below the average analyst price target of $31.25.